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OBJECTIVES: We tested the noninferiority of a fast-track rule-out protocol for the diagnosis of non-ST-
segment elevation myocardial infarction vs noncoronary chest pain based on the single-sampling combined
assessment of medium-sensitivity cardiac troponin I and ultra-sensitive copeptin compared with the serial
assessment of medium-sensitivity cardiac troponin I.
METHODS: Ultra-sensitive copeptin and medium-sensitivity cardiac troponin I levels were measured at
presentation in 196 consecutive patients admitted to the emergency department for acute nontraumatic chest
pain within 6 hours from symptoms onset and without ST-segment elevation on a 12-lead electrocardio-
gram. The diagnostic performance for non-ST-segment elevation myocardial infarction diagnosis of the
dual-marker single-sampling strategy with medium-sensitivity cardiac troponin I and ultra-sensitive
copeptin on admission was compared with that of the serial 0- and 3-hour medium-sensitivity cardiac
troponin I sampling in reference to the adjudicated postdischarge diagnosis, using both the comparison of
area under the curve (AUC) receiver operating characteristic and the McNemar chi-square test.
RESULTS: The diagnosis of non-ST-segment elevation myocardial infarction was adjudicated in 29 patients
(14.8%). The combination of medium-sensitivity cardiac troponin I and ultra-sensitive copeptin generated
an AUC of 0.87 (95% conﬁdence interval, 0.82-0.91), which was noninferior with respect to the 3-hour
interval medium-sensitivity cardiac troponin I serial sampling (P ¼ .194 for AUC difference). The com-
bination of medium-sensitivity cardiac troponin I and ultra-sensitive copeptin also yielded a numerically
higher diagnostic sensitivity (100% vs 89.7%; P ¼ not signiﬁcant).
CONCLUSIONS: Asingle-sampling strategyof combinedultra-sensitive copeptin andmedium-sensitivity cardiac
troponin I is noninferior to a 0- and 3-hour serial medium-sensitivity cardiac troponin I sampling in ruling out
non-ST-segment elevation myocardial infarction and thus may allow an earlier discharge of patients who are
ruled out for non-ST-segment elevation myocardial infarction (ClinicalTrials.gov Identiﬁer NCT01962506).
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).  The American Journal of Medicine (2016)
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106 The American Journal of Medicine, Vol 129, No 1, January 2016The rapid and reliable ruling out of non-ST-elevation
myocardial infarction in patients who are admitted to the
emergency department for acute chest pain is a major unmet
clinical need.1 In the absence of ST elevation at the stand-
ard electrocardiogram (ECG), evaluation of cardiac tropo-
nins is currently the gold standard for the diagnosis ofCLINICAL SIGNIFICANCE
 We tested the noninferiority of a fast-
track rule-out protocol for the diag-
nosis of non-ST-segment elevation
myocardial infarction vs noncoronary
chest pain based on the single-sampling
combined assessment of high-sensitivity
cardiac troponin I and ultra-sensitive
copeptin compared with the serial
assessment of high-sensitivity cardiac
troponin I.
 In this study, such single-sampling
strategy, proving noninferior to a 0-
and 3-hour serial high-sensitivity car-
diac troponin I sampling in ruling out
non-ST-segment elevation myocardial
infarction, may thus allow an earlier
discharge of patients ruled out for
non-ST-segment elevation myocardial
infarction.non-ST-segment elevation
myocardial infarction.2,3 However,
a normal single value from a
contemporary cardiac troponin
assay—not exceeding the 99th
percentile of a normal reference
population—on admission does
not effectively rule out an evolving
myocardial infarction because of
the delayed release kinetics of
cardiac troponin (the cardiac
troponin “blind period”).4,5 High-
sensitivity cardiac troponin as-
says, the deﬁnition of which has
changed over time,6 improve
sensitivity compared with most
contemporary cardiac troponin as-
says. Although it is not clear that
this improvement in performance
would bring additional value in the
clinical setting,6 these assays now
are considered to be preferable for
their ability to detect early minor
increases in the analyte,7 but even
with these assays there may be still
a short “blind period” in cases of
early admissions. Therefore, current European Society of
Cardiology (ESC) guidelines for pain-free patients with a
Global Registry of Acute Cardiac Events score <140
recommend a “rapid” rule-out protocol for non-ST-segment
elevation acute coronary syndromes with serial sampling of
high-sensitivity cardiac troponin within 3 hours (class I
recommendation, level of evidence B).8 Both the ESC and
the American College of Cardiology/American Heart Asso-
ciation guidelines8,9 highlight the importance of the time
interval from chest pain onset to hospital admission. In rec-
ommending the use of high-sensitivity cardiac troponin, the
ESC guidelines suggest retesting after 3 hours if patient
presentation is within 6 hours from symptom onset or
in cases in which this information cannot be reliably ob-
tained. A dual sampling strategy is not needed with later
presentations.10
The need for serial blood sampling in an emergency
department to rule out non-ST-segment elevation myocardial
infarction in patients presenting early is not ideal, because it
does not allow an immediate diagnosis and a quick patient
triage on presentation. Therefore, a fast-track rule-out proto-
col based onmulti-marker single-sampling strategies has been
advocated.11 Among emerging biomarkers in myocardial
infarction, copeptin has a virtually immediate increase and
rapid decrease,11 which complements the diagnosticinformation of cardiac troponin. Copeptin, also known as C-
terminal pro-arginine-vasopressin, is a 39 amino acid peptide
derived from pre-pro-vasopressin and reﬂects arginine-
vasopressin release with a 1:1 stoichiometric generation
ratio. Activation of the arginine-vasopressin systemmaymark
the individual’s response to acute endogenous stress, asoccurs in acute myocardial infarc-
tion.12 Two large cohort studies
have demonstrated that levels of
copeptin are increased during acute
myocardial infarction,13,14 and that
the combined determination of
copeptin and medium-sensitivity
cardiac troponin in patients pre-
senting early with myocardial
infarction allows for a rapid and
safe ruling out of acute myocardial
infarction.13,14 A recent controlled
trial has shown that early discharge
of low- to intermediate-risk pa-
tients with suspected acute coro-
nary syndromes and both negative
copeptin and troponin at admission
is safe, with the potential for
reducing costs and shortening stay
in the emergency department.15
However, the diagnostic accuracy
of a combination of both the newer
ultra-sensitive copeptin assay and
the medium-sensitivity cardiac
troponin for the instant rule out of
non-ST-segment elevation myo-cardial infarction has not been tested prospectively within the
6-hour time window of symptom onset.
Therefore, we designed the ultra-sensitive COPeptin in
addition to medium sensitivity cardiac troponin for the early
diagnosis of non-ST-elevation Acute Coronary Syndromes
(COPACS) study to test the hypothesis of a diagnostic non-
inferiority for a dual-marker single-sampling strategy based
on the combination of ultra-sensitive copeptin and medium-
sensitivity cardiac troponin I compared with both single and
serial assessments (0 and 3 hours) of medium-sensitivity
cardiac troponin for the early diagnosis of non-ST-segment
elevation myocardial infarction in patients admitted within 6
hours of chest pain onset.MATERIALS AND METHODS
Study Design
The COPACS study was a prospective cohort single-center
study carried out from July to December 2013, complying
with the Declaration of Helsinki and approved by the Ethics
Committee of the “G. d’Annunzio” University. The study
was registered prospectively (ClinicalTrials.gov Identiﬁer
NCT01962506). Each patient gave written informed consent
before participation.
Ricci et al Ultra-sensitive Copeptin in Non-ST-Segment Elevation-Acute Coronary Syndrome 107Selection of Participants
We screened all consecutive patients who were admitted to
the emergency department because of acute nontraumatic
chest pain with chest pain onset within the previous 6 hours
in a time interval of 6 months. Exclusion criteria included
age <18 years, patients presenting with ST-segment eleva-
tion myocardial infarction or new-onset left bundle branch
block, and cardiac arrest survivors. Subjects with any
missing data, who were lost to follow-up, or in whom serum
interferences with the assay were found in accordance with
Clinical and Laboratory Standards Institute guideline EP
7-A216 (ie, bilirubin >5 mg/dL, triglycerides >5 mg/L, al-
bumin >5 g/dL, or hemolysis in the sample) were excluded
from statistical analyses. Of 210 eligible patients, 14 were
excluded because of missing clinical data or no available
follow-up (n ¼ 8) and for insufﬁcient sampling, freezing
problems, or serum interferences (n ¼ 6). The ﬁnal study
population consisted of 196 patients.
Clinical Assessment
On admission, all patients enrolled underwent a clinical
assessment, including medical history, physical evaluation,
screening blood tests (serum electrolytes and creatinine),
chest x-ray, and an echocardiogram or a coronary angiogram
at the discretion of the emergency medicine physicians. In all
patients, medium-sensitivity cardiac troponin I was measured
on admission and, serially, after 3 and 6 and 12 hours. A
12-lead ECG was obtained at the same time points. Blood
samples for determination of ultra-sensitive copeptin were
collected only on admission. In addition to these assessments,
the pretest probability of coronary artery disease was evalu-
ated for each patient by means of the Chest Pain Score17,18
and the Thrombolysis in Myocardial Infarction risk score.19
Final Diagnosis
The ﬁnal diagnosis for each patient was adjudicated inde-
pendently by 2 cardiologists (FR and DDP, among the study
authors), blinded to ultra-sensitive copeptin values, on the
basis of all available data; disagreements were settled by
consensus. Further investigations and treatment of patients
were not affected by the study. At 90 (10) days, clinical
events were recorded with a face-to-face visit or through
telephone contact with the patients, their general practi-
tioners, or the hospitals where they were readmitted. Non-
ST-segment elevation myocardial infarction was deﬁned as
per the Universal Myocardial Infarction Deﬁnition.3 Non-
coronary chest pain was deﬁned in the presence of a clear
noncoronary chest pain alternative diagnosis.
Biomarker Testing
Blood samples for measurement of ultra-sensitive cope-
ptin were collected in tubes containing potassium ethyl-
enediaminetetraacetic acid, centrifuged, and frozen at80C.
Copeptin was measured by the BRAHMS copeptin ultra-
sensitive immunoluminometric assay on the KRYPTORCompact Plus system (Thermo Fisher Scientiﬁc, Hennigsdorf,
Germany). This assay has a lower limit of detection of 0.9
pmol/L and a functional assay sensitivity of <2 pmol/L. The
direct measuring range was 0.9 to 500 pmol/L. The 95th
centile among healthy participants was <10 pmol/L. This
threshold of 10 pmol/L was chosen with reference to Keller
et al,13 who determined different cutoffs in a reference pop-
ulation and tested their diagnostic performance in a population
with acute coronary syndromes. Serum concentration of car-
diac troponin I was measured using a guideline-acceptable,20
now properly labeled “medium-sensitivity,”6,21 Dimension
VISTA cardiac troponin I assay (Siemens Healthcare Di-
agnostics, Erlangen, Germany). The analytic evaluation of the
assay established by the manufacturer yielded a limit of blank
of this assay of 0.015 mg/L, with the 99th centile concentration
of 0.045 mg/L and the lowest concentration measurable with a
coefﬁcient of variation<10% of 0.040 mg/L. The 99th centile
(0.045 mg/L) of the value distribution in normal subjects was
used as the diagnostic cutoff to fulﬁll the Universal Myocar-
dial Infarction Deﬁnition criteria.3Statistical Analysis
We calculated a sample size of 180 patients to achieve 80%
power to detect a noninferiority difference of 0.10 between the
area under the curve (AUC) receiver operating characteristic
under the null hypothesis of 0.80 and an AUC under the
alternative hypothesis of 0.90 using a 1-sided z test at a sig-
niﬁcance level (alpha) of 5% on the basis of the noneST-
segment elevation myocardial infarction incidence among the
population of subjects presenting to our emergency depart-
ment with chest pain onset <6 hours, as well as previous
studies.14,22 These calculations were performed using PASS
2005 software (NCSS Statistical Software, Kaysville, UT).
Continuous variables are presented as mean  standard de-
viation or median with interquartile range. Means were
compared using the Student t test for normally distributed
variables or the Wilcoxon rank-sum test or ManneWhitney
test for data not ﬁtting the assumptions of parametric testing.
Categoric variables are reported as distribution of frequency,
absolute and percentage, and compared using chi-square
analysis or Fisher exact test as appropriate. Biomarkers were
treated as categoric variables (positive or negative) at the
prespeciﬁed cutoffs. Receiver operating characteristic curves
were constructed to assess the sensitivity, speciﬁcity, and
positive and negative predictive values (with their 95% con-
ﬁdence interval). Comparisons of AUCs were performed ac-
cording to Hanley and McNeil.23 A margin to deﬁne
noninferiority between AUCs was set at <0.05. Sensitivity
and speciﬁcity were compared with the McNemar chi-square
test.24 All tests were 2-tailed, and a P value <.05 was
considered statistically signiﬁcant. Statistical analysis was
performed using the 2004 SPSS (Advanced Statistical 13;
SPSS Inc, Chicago, IL), MedCalc 10.3.2.0 for Windows
(MedCalc Software, Mariakerke, Belgium), and the R open
source software.
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Baseline Characteristics, Outcomes, and Final
Diagnosis
Baseline characteristics of the study population are summa-
rized in Table 1. In 29 patients (14.8%), the ﬁnal adjudicated
diagnosis was non-ST-segment elevation myocardial
infarction. They had a signiﬁcantly lower glomerular
ﬁltration rate and a higher Thrombolysis in Myocardial
Infarction risk score compared with subjects with
noncoronary chest pain; of note, the Chest Pain Score was
similar in the 2 groups. Diagnoses in the 167 patients with
noncoronary chest pain were cardiac related in 12 cases
(7%) (acute heart failure in 3, atrial ﬁbrillation in 1,
myopericarditis in 1, hypertensive emergency in 5, severe
valvular aortic stenosis in 1, and Takotsubo syndrome
in 1) and noncardiac-related in 75 cases (44.9%) (eg,Table 1 Baseline Characteristics of Patients in Relation to Final Diag
All (n ¼ 196)
Age (y), mean  SD 61.4  16.2
Gender (male), n (%) 126 (64.3)
Cardiovascular risk factors, n (%)
Hypertension 119 (60.7)
Dyslipidemia 59 (30.1)
Diabetes 38 (19.4)
BMI >30 kg/m2 49 (25.0)
Family history of premature CAD 48 (24.5)
Active smoking 48 (24.5)
Medical history, n (%)
Previous myocardial infarction 42 (21.4)
Heart failure 6 (3.1)
Previous PCI or CABG 30 (15.3)
Stable angina 6 (3.1)
Unstable angina 13 (6.6)
ST- or T-wave abnormality 39 (19.8%)
Pharmacologic treatment, n (%)
Aspirin 50 (25.5)
Clopidogrel 14 (7.1)
Prasugrel 3 (1.5)
Beta-blockers 46 (23.5)
ACEIs/ARBs 74 (37.8)
Chest pain onset, n (%)
<3 h 124 (63.3)
3-6 h 72 (36.7)
Creatinine (mg/dL), mean  SD 0.92  0.58
eGFR (mL/min/1.73 m2), mean  SD 82.7  14.9
TIMI risk score, median (IQR) 1 (0-2)
Chest Pain Score, median (IQR) 5 (4-7)
Data are presented as n (%) of patients unless otherwise indicated.
ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin recept
CAD¼ coronary artery disease; eGFR¼ estimated glomerular ﬁltration rate; IQR ¼
NSTEMI ¼ non-ST-elevation myocardial infarction; PCI ¼ percutaneous coronary
Infarction.
*Chi-square test.
†Student t test for unpaired data.
‡ManneWhitney U test.pneumothorax, pleural effusion, pancreatitis, cholecystitis);
no cause was identiﬁed in the remaining patients (Figure 1).
Ultra-sensitive copeptin was higher in patients with non-ST-
segment elevation myocardial infarction compared with
noncoronary chest pain (Figure 2). Baseline characteristics
of the study population across ultra-sensitive copeptin quar-
tiles are shown in Table 2. In-hospital and 90-day outcomes
are summarized in Table 3. Among patients with an ultra-
sensitive copeptin/medium-sensitivity cardiac troponin I
pattern (124/196, 63%), hospital readmission was required in
9.6% of cases, but no adverse cardiac event was experienced
at 90 days. Among patients with an ultra-sensitive copeptinþ/
medium-sensitivity cardiac troponin I pattern, non-ST-
segment elevation myocardial infarction was diagnosed later
(>3 hours) during hospital stay in 6.4% of patients and after
discharge adverse cardiac events occurred in 4.2% of
patients.nosis
NSTEMI (n ¼ 29) NCCP (n ¼ 167) P Value*
64.9  15.0 60.8  16.4 .213†
21 (72.4) 105 (62.9) NS
20 (69.0) 99 (59.3) NS
11 (37.9) 48 (28.7) NS
9 (31.0) 29 (17.4) NS
8 (27.6) 41 (24.6) NS
9 (31.0) 39 (23.4) NS
8 (27.6) 40 (24.0) NS
9 (31.0) 33 (19.8) NS
1 (3.4) 5 (3.0) NS
5 (17.2) 25 (15.0) NS
0 6 (3.6) NS
4 (13.8) 9 (5.4) NS
21 (72.4) 18 (10.7) <.001
10 (34.5) 40 (24.0) NS
2 (6.9) 12 (7.2) NS
1 (3.4) 2 (1.2) NS
7 (24.1) 39 (23.4) NS
10 (34.5) 64 (38.3) NS
14 (48.3) 110 (65.9) NS
15 (51.7) 57 (34.1)
1.25  1.27 0.86  0.31 .001†
75.9  22.1 83.9  12.9 .007†
2 (2-3) 1 (0-2) <.001‡
6 (5-6.8) 5 (4-7) NS‡
or blocker; BMI ¼ body mass index; CABG ¼ coronary artery bypass graft;
interquartile range; NCCP¼ noncoronary chest pain; NS¼ not signiﬁcant;
intervention; SD ¼ standard deviation; TIMI ¼ Thrombolysis in Myocardial
Figure 1 Flow chart of the recruitment and selection process, with biomarker results on admission and
adjudicated ﬁnal diagnoses. The asterisk (*) indicates that in the subgroup of patients with non-ST-
segment elevation myocardial infarction presenting with a discordant ultra-sensitive copeptinþ/medium-
sensitivity cardiac troponin I pattern on admission, a third high-sensitivity cardiac troponin I sample at
>6 hours was required to conﬁrm the diagnosis of non-ST-segment elevation myocardial infarction in 3
patients. Cop-cTnI ¼ copeptin cardiac troponin I; NCCP ¼ noncoronary chest pain; NSTEMI ¼ with
non-ST-segment elevation myocardial infarction.
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Troponin-I and Ultra-Sensitive Copeptin
Measurements
Ultra-sensitive copeptin and medium-sensitivity cardiac
troponin I were discordant in 57 cases (29%) on admission.
Speciﬁcally, on admission, 47 patients presented with an ultra-
sensitive copeptinþ/medium-sensitivity cardiac troponin
I pattern; 8 (17%) of these had a 3-hour positive medium-
sensitivity cardiac troponin, and 39 (82.9%) had a conﬁrmed
negative medium-sensitivity cardiac troponin I on retesting.
Among those 8 patients with a positive medium-sensitivity
cardiac troponin I retest, 3 patients were classiﬁed as having
a noneST-segment elevation myocardial infarction, and a
cardiac-related noncoronary chest pain diagnosis was estab-
lished in the other 5. Among those 39 patients with a second
medium-sensitivity cardiac troponin I negative test at 3 hours,
in 3 patients a medium-sensitivity cardiac troponin I increase
was detected beyond 6 hours, and a non-ST-segment elevation
myocardial infarction was ﬁnally diagnosed.
An ultra-sensitive copeptin/medium-sensitivity cardiac
troponin Iþ pattern was documented on admission in 10
patients: A ﬁnal diagnosis of non-ST-segment elevation
myocardial infarction was adjudicated in 9 patients and of
noncoronary chest pain in 1 patient with a hypertensive
emergency.The delay from chest pain onset to emergency depart-
ment admission was signiﬁcantly shorter among subjects
presenting with an ultra-sensitive copeptinþ/medium-sensi-
tivity cardiac troponin I pattern (60  23 minutes) than in
those with an ultra-sensitive copeptin/medium-sensitivity
cardiac troponin Iþ pattern (300  42 minutes; P < .001).
Diagnostic performances of the combined ultra-sensitive
copeptin/medium-sensitivity cardiac troponin I on admis-
sion vs the serial medium-sensitivity cardiac troponin I
sampling at 0 and 3 hours, and vs the singlems-cTnI sampling
on admission are summarized in Table 4. The dual-marker
single-sampling strategy based on the ultra-sensitive copep-
tin/medium-sensitivity cardiac troponin I combination
correctly ruled out non-ST-segment elevation myocardial
infarction with 100% sensitivity and 100% negative predic-
tive value. The overall diagnostic performance of combined
ultra-sensitive copeptin/medium-sensitivity cardiac troponin
I single-sampling strategy was noninferior to the serial
assessment of medium-sensitivity cardiac troponin I within
3 hours (AUC difference 0.068, P ¼ not signiﬁcant).
Sensitivity (100% vs 89.7%; P¼ not signiﬁcant) was also not
signiﬁcantly different. Sensitivity of the single-sampling
strategy with ultra-sensitive copeptin/medium-sensiti-
vity cardiac troponin I for the rapid ruling out of non-ST-
segment elevation myocardial infarction was higher than
Figure 2 Box-whisker graphs of ultra-sensitive copeptin
levels in the groups with noncoronary chest pain and
noneST-segment elevation myocardial infarction. Box-
whisker plots show the 25th and 75th percentile ranges
(box) with 95% conﬁdence intervals (whiskers) and me-
dian values (transverse lines in the box). Statistically
signiﬁcant differences were found between the 2 groups
(P < .001, ManneWhitney U test). NCCP ¼ noncoronary
chest pain; NSTEMI ¼ non-ST-elevation myocardial
infarction.
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(100% vs 79.3%; P ¼ .031).DISCUSSION
This study showed that a dual-marker single-sampling
strategy based on the ultra-sensitive copeptin/medium-
sensitivity cardiac troponin I combination is a safe and
effective strategy for the fast-track ruling out of non-ST-
segment elevation myocardial infarction in low- to
intermediate-risk patients presenting to the emergency
department <6 hours from chest pain onset. Our study
focused on a population of patients in whom the ECG is not
suggestive for ST-segment elevation myocardial infarction,
in whom diagnostic uncertainty is maximum, and in whom
the crucial diagnostic decision has to be between non-ST-
segment elevation myocardial infarction and noncoronary
chest pain. In our population, a concordant ultra-sensitive
copeptin/medium-sensitivity cardiac troponin I pattern
correctly ruled out non-ST-segment elevation myocardial
infarction, with both excellent diagnostic sensitivity and
negative predictive value, and would have thus allowed an
immediate and safe discharge of approximately 65% of our
cases. The subgroup of patients had an uneventful 3-month
follow-up. In this study, the overall diagnostic performance
and the sensitivity of dual-marker single-sampling strategy
based on the ultra-sensitive copeptin/medium-sensitivity
cardiac troponin I combination on admission were non-
inferior to medium-sensitivity cardiac troponin I retesting at
3 hours. The dual-marker strategy showed a signiﬁcantly
higher diagnostic sensitivity to identify non-ST-segment
elevation myocardial infarction than the single sampling of
medium-sensitivity cardiac troponin I alone. The possibility
of a very early rule out of non-ST-segment elevationmyocardial infarction25,26 based on the combination of
complementary pathophysiologic information derived from
the quantiﬁcation of myocardial necrosis (cardiac troponin I)
and acute endogenous stress response (copeptin) seems to
be real and effective.
Copeptin provides little clinical information when
measured alone because of its nonspeciﬁc elevation in many
pathophysiologic conditions.14,27 However, its advantage is
in the almost immediate increase in plasma concentration
after the onset of chest pain, with a rapid decline afterward
over the ﬁrst 6 to 12 hours. Therefore, its assessment seems
to be valuable only in the cohort of patients presenting early
with suspected acute coronary syndrome, which was indeed
the focus of our study.
Our study corroborates and extends previous ﬁndings
supporting the viability of the dual-marker single-sampling
strategy based on the combination of copeptin and cardiac
troponin.4,13,14,28 Overall, positive results of the combined
copeptin-cardiac troponin were supported recently by a
meta-analysis from 13 observational studies,29 in which the
authors documented that the addition of copeptin to cardiac
troponin not only identiﬁes the patients at risk of all-cause
death but also improves the sensitivity and negative likeli-
hood ratio for the diagnosis of non-ST-segment elevation
myocardial infarction compared with cardiac troponin I
alone. The outcomes of such comparisons are likely to be
strongly inﬂuenced by patient selection (eg, including or
excluding those with ST-segment elevation myocardial
infarction, in whom the diagnostic uncertainty is trivial),
timing of presentation (including or excluding patients
presenting late), and the choice of the comparator (ie,
contemporary, ﬁrst-, second-, or third-generation cardiac
troponin assay).6,20,30 Therefore, proper comparisons of
alternative strategies should rely on the appropriate selection
of the target population and the latest generation assays.
The large multicenter Biomarkers in Cardiology-8 trial
recently randomized 902 patients within 12 hours of chest pain
onset to serial cardiac troponin (0 and 3-6 hours) or the com-
bined copeptin and cardiac troponin evaluation, and docu-
mented that patients with negative ﬁndings in both groups
were all eligible for discharge and had a similar rate of adverse
events.15 A limitation of that study is the inclusion of patients
admitted at >6 hours, when the contribution of adding
copeptin and even of the dual sampling of cardiac troponin
over single-sampling cardiac troponin is likely negligible.
Only 3 other studies restricted patient eligibility to a delay from
symptom onset to admission <6 hours.4,31,32 Meune et al31
compared the combined standard copeptin and cardiac
troponin evaluation with the serial cardiac troponin evaluation
using a high-sensitivity cardiac troponin I assay, but general-
izability of such results seems to be limited because of the
small sample size in that study (n ¼ 56). Chenevier-Gobeaux
et al32 reported a 98% sensitivity and a 99% negative predic-
tive value for the combination of standard copeptin and cardiac
troponin I in ruling out acute coronary syndromes, but the
cardiac troponin assays used should not be considered as
“guideline acceptable” because of analytic imprecision.3,30 The
Table 2 Baseline Characteristics of Patients Across Quartiles of Ultrasensitive Copeptin
4.2 pmol/L
(n ¼ 45)
4.2-7.4 pmol/L
(n ¼ 45)
7.4-13.8 pmol/L
(n ¼ 41)
>13.8 pmol/L
(n ¼ 44) P Value*
Age (y), mean  SD 56.0  13.6 55.2  17.5 64.3  15.9 69.9  14.0 <.001†
Gender (male), n (%) 18 (40.0) 26 (57.8) 35 (85.4) 30 (68.2) <.001
Cardiovascular risk factors, n (%)
Hypertension 22 (48.9) 22 (48.9) 27 (65.9) 32 (72.7) .046
Dyslipidemia 12 (26.7) 12 (26.7) 14 (34.1) 13 (29.5) NS
Diabetes 6 (13.3) 8 (17.8) 9 (22.0) 9 (20.5) NS
BMI >30 kg/m2 8 (17.8) 11 (24.4) 9 (22.0) 12 (27.3) NS
Family history of premature CAD 8 (17.8) 12 (26.7) 14 (34.1) 8 (18.2) NS
Active smoking 9 (20.0) 16 (35.6) 11 (26.8) 8 (18.2) NS
Medical history, n (%)
Previous myocardial infarction 5 (11.1) 6 (13.3) 11 (26.8) 12 (27.3) NS
Heart failure 0 0 3 (7.3) 3 (6.8) NS
Previous PCI or CABG 5 (11.1) 5 (11.1) 9 (22.0) 6 (13.6) NS
Stable angina 1 (2.2) 1 (2.2) 0 0 NS
Unstable angina 3 (6.7) 2 (4.4) 3 (7.3) 3 (6.8) NS
Pharmacologic treatment, n (%)
Aspirin 6 (13.3) 8 (17.8) 15 (36.6) 13 (29.5) .045
Clopidogrel 3 (6.7) 1 (2.2) 3 (7.3) 4 (9.1) NS
Prasugrel 2 (4.4) 0 1 (2.4) 0 NS
Beta-blockers 8 (17.8) 8 (17.8) 12 (29.3) 11 (25.0) NS
ACEIs/ARBs 15 (33.3) 13 (28.9) 14 (34.1) 21 (47.7) NS
Chest pain onset, n (%)
<3 h 33 (73.3) 24 (53.3) 27 (65.9) 28 (63.6) NS
3-6 h 12 (26.7) 21 (46.7) 14 (34.1) 16 (36.4)
Creatinine (mg/dL), mean  SD 0.7  0.2 0.8  0.2 0.9  0.2 1.2  1.0 <.001†
eGFR (mL/min/1.73 m2), mean  SD 88.2  3.8 87.8  6.5 82.8  13.0 74.2  20.6 <.001†
TIMI risk score, median (IQR) 1 (0-1) 1 (0-2) 1 (0-2) 2 (1-3) <.001‡
CHEST PAIN score, median (IQR) 5 (3.5-7) 5 (3-7) 5 (4-8) 5 (4-7) NS‡
Data are presented as n (%) of patients unless otherwise indicated.
ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; BMI ¼ body mass index; CABG ¼ coronary artery bypass graft;
CAD ¼ coronary artery disease; eGFR ¼ estimated glomerular ﬁltration rate; IQR ¼ interquartile range; NS ¼ not signiﬁcant; PCI ¼ percutaneous coronary
intervention; SD ¼ standard deviation; TIMI ¼ Thrombolysis in Myocardial Infarction.
*Chi-square test.
†One-way analysis of variance test.
‡KruskaleWallis H test.
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detection Of Patients with acute myocardial Infarction study4
used a contemporary medium-sensitivity cardiac troponin I
assay (10% coefﬁcient of variation at 99th percentile of 30
ng/L). The combination of standard copeptin and medium-
sensitivity cardiac troponin I at presentation provided a nega-
tive predictive value>99%, with the potential to rule out non-
ST-segment elevation myocardial infarction in 58% of cases
without serial blood sampling.4 However, the adjudication of
events was predicated on local cardiac troponin results. In our
study, we kept the patients in to ensure complete ascertainment
of the ﬁnal diagnosis. Our study, with patients managed
similarly in a single emergency department, conﬁrms such
results, also using the recently introduced ultra-sensitive
copeptin, which should allow a better detection of borderline
elevations of this biomarker. Although the added value of such
a sensitive copeptin assay cannot be inferred from our data, no
previous study has used such a combination of sensitive
biomarkers.Study Limitations
We acknowledge a few limitations of the present study.
First, this was a single-center study with limited population
size. Yet, sample size was calculated on the basis of a ful-
ﬁlled noninferiority hypothesis, with an observed preva-
lence of non-ST-segment elevation myocardial infarction
similar to that in previous larger studies on the same
topic.13,33,34 Second, because of the lack of statistical power
within subgroups, we could not evaluate the impact of
pretest probability on the diagnostic accuracy of different
biomarker strategies.32 Third, we did not compare the
diagnostic accuracy of a combined assessment of ultra-
sensitive copeptin and medium-sensitivity cardiac troponin
I with a shorter delay (eg, 1 hour) in medium-sensitivity
cardiac troponin I retesting, as recently proposed.35 Last,
serum cardiac troponin I concentrations were not measured
with a high- or ultra-high sensitivity assay. Nonetheless, our
medium-sensitivity assay has a performance target of
Table 3 Outcomes Related to Ultrasensitive Copeptin and Medium-Sensitivity Cardiac Troponin I Values at Admission to the Emergency
Department
us-Cop/ms-cTnIþ
(n ¼ 10)
us-Copþ/ms-cTnI
(n ¼ 47)
us-Copþ/ms-cTnIþ
(n ¼ 15)
us-Cop/ms-cTnI
(n ¼ 124)
Outcome during hospital stay
UA 0 (0) 0 (0) 0 (0) 0 (0)
NSTEMI 9 (90) 6 (12.8) 14 (93.3) 0 (0)
Coronary angiography 7 (70) 6 (12.8) 13 (86.7) 0 (0)
PCI 6 (70) 5 (10.6) 8 (53.3) 0 (0)
CABG 0 (0) 1 (2.1) 4 (26.7) 0 (0)
AHF 0 (0) 2 (4.3) 9 (60) 0 (0)
CV death 0 (0) 0 (0) 2 (13.3) 0 (0)
Non-CV death 0 (0) 0 (0) 0 (0) 0 (0)
Outcome at 90 d of follow-up
Readmission to ED for NCCP 1 (10) 6 (12.7) 2 (13.3) 12 (9.6)
UA 1 (10) 1 (2.1) 0 (0) 0 (0)
STEMI 0 (0) 0 (0) 0 (0) 0 (0)
NSTEMI 0 (0) 1 (2.1) 1 (6.7) 0 (0)
Coronary angiography 1 (10) 2 (4.3) 1 (6.7) 0 (0)
PCI 1 (10) 1 (2.1) 1 (6.7) 0 (0)
CABG 0 (0) 0 (0) 0 (0) 0 (0)
AHF 0 (0) 0 (0) 1 (6.7) 0 (0)
CV death 0 (0) 1 (2.1) 0 () 0 (0)
Non-CV death 0 (0) 0 (0) 0 (0) 0 (0)
Data are presented as n (%) of patients.
AHF ¼ acute heart failure; CABG ¼ coronary artery bypass graft; CV ¼ cardiovascular; ED ¼ emergency department; ms-cTnI ¼ medium-sensitivity
cardiac troponin I; NCCP ¼ noncoronary chest pain; NSTEMI ¼ non-ST-elevation myocardial infarction; PCI ¼ percutaneous coronary intervention;
STEMI ¼ ST-elevation myocardial infarction; UA ¼ unstable angina; us-Cop ¼ ultrasensitive copeptin.
112 The American Journal of Medicine, Vol 129, No 1, January 2016measuring cardiac troponin with a 10% coefﬁcient of vari-
ation at the 99th percentile of the reference population, is
currently classiﬁed as “guideline acceptable,”30 and is in the
sensitivity range of tests currently approved for use in the
United States.6 Furthermore, a previous study by Keller
et al36 reported that among 1818 patients with suspected
acute myocardial infarction, a serial change in cardiac
troponin I levels within 3 hours from admission (using the
99th percentile diagnostic cutoff value) would have deter-
mined a 99% negative predictive value and a 96% positive
predictive value for both high-sensitivity cardiac troponin I
and medium-sensitivity cardiac troponin I assays. However,
whether the use of a higher sensitivity cardiac troponin
assay would have changed the main message of this studyTable 4 Comparison of the Diagnostic Performances of Various Biom
Infarction vs Noncoronary Chest Pain with Time Between Chest Pain On
Biomarker Strategy
Sensitivity
(P value)* Speciﬁcity
Serial ms-cTnI at 3 h 89.7% (.250) 98.2%
ms-cTnI on admission 79.3% (.031) 98.8%
us-Cop/ms-cTnI on admission 100% 74.2%
Adjudicated ﬁnal diagnosis by 2 independent cardiologists blinded to the re
AUC ¼ area under the curve; CI ¼ conﬁdence interval; ms-cTnI ¼ me
PPV ¼ positive predictive value; us-Cop ¼ ultrasensitive copeptin.
*McNemar test comparing sensitivity of Cop-us/ms-cTnI.
†Hanley method comparing AUC of serial ms-cTnI.remains questionable, because increased diagnostic sensi-
tivity of the cardiac troponin assay is likely to reduce, but
not eliminate, the troponin-blind period after the onset of a
myocardial infarction.CONCLUSIONS
In patients presenting to the emergency department within
6 hours for acute chest pain, a strategy of single-sampling
dual-marker ultra-sensitive copeptin/medium-sensitivity
cardiac troponin I is noninferior to serial medium-sensitivity
cardiac troponin I sampling in allowing a rapid and reliable
ruling out of non-ST-segment elevation myocardial infarc-
tion, and may thus obviate the need for prolongedarker Strategies for the Diagnosis of Non-ST-Elevation Myocardial
set and Emergency Department Admission <6 Hours
PPV NPV AUC (95% CI)
AUC Difference
(P Value)†
89.7% 98.2% 0.939 (0.896-0.968) -
92% 96.5% 0.891 (0.838-0.931) 0.049 (.117)
40.3% 100% 0.871 (0.816-0.915) 0.068 (.194)
sults of copeptin.
dium-sensitivity cardiac troponin I; NPV ¼ negative predictive value;
Ricci et al Ultra-sensitive Copeptin in Non-ST-Segment Elevation-Acute Coronary Syndrome 113monitoring and serial blood biomarker sampling. The
diagnostic utility of ultra-sensitive copeptin may result in
substantial beneﬁts for both healthcare providers and pa-
tients, decreasing costs and reducing self-discharge and
readmission rates.
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